VHL pathogenic variants
About
Gene context: VHL
Biomarker Type: Germline Variant
Present: True
Chromosome: 3
Requires Pathogenic: True
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | VHL pathogenic variants | Renal Cell Carcinoma | Belzutifan | |
| FDA (1) | VHL pathogenic variants | Central Nervous System Hemangioblastoma | Belzutifan | |
| FDA (1) | VHL pathogenic variants | Pancreatic Neuroendocrine Tumor | Belzutifan |